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Tadalafil, a long-acting PED-5 inhibitor, is commonly used for the treatment of pulmonary arterial 
hypertension (PAH). However, its efficacy and clinical application are severely limited by the poor 
water solubility, low bioavailability and a series adverse effects (e.g. headaches, indigestion). In this 
study, tadalafil was prepared and loaded into biodegradable PLGA (poly(lactic-co-glycolic acid)) 
microspheres (TDF-PLGA-MS) via emulsification-solvent evaporation. The resulting microspheres were 
processed into pulmonary inhalant by freeze drying. The TDF-PLGA-MS was spherical and uniform, 
with an average particle diameter ~10.29 μm. The encapsulation efficiency and drug loading yield of 
TDF-PLGA-MS were 81.68% and 8.52%, respectively. The investigation of micromeritics showed 
that the TDF-PLGA-MS had low moisture content. The fluidity of powders was relatively good. The 
aerodynamic diameter and emptying rate of microspheres powders were 3.92 μm and 95.41%, respectively. 
Therefore, the microspheres powders were easy to be atomized, and can meet the requirements of 
pulmonary administration. In vitro release results showed that the microspheres group released slowly. The 
cumulative release in 24 h and 10 d was 46.87% and 84.06%, respectively. The in vitro release profile of 
TDF-PLGA-MS was in accordance with the Weibull model. The results of Pharmacokinetics showed that 
tadalafil from microspheres slowly released into the blood after intratracheal instillation. The pulmonary 
drug residue in 0.5 h was 3.5 times compared with solution group. The residual concentration in lung 
after 10d was still higher than that of solution group in 48 h. The t1/2β and MRT0-∞ were 3.10 times and 
3.96 times that of solution group, respectively. Moreover, the Cmax and AUC of drug residues in lung  were 
3.48 times and 16.36 times that of solution group, respectively. The results of tissue distribution showed 
that the Re in lung was 16.358, which indicated the lung targeting. In conclusion, the TDF-PLGA-MS 
for pulmonary administration in this study can significantly improve the pulmonary targeting, increase 
efficacy of tadalafil and reduce other non-target organs toxicity. This study will have an important clinical 
significance for PAH patients who need long-term drug therapy.
Keywords: Pulmonary arterial hypertension. Tadalafil. PLGA. Microspheres. Pulmonary administration. 
Micromeritic. In vitro release. Pharmacokinetic. Tissue distribution.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a 
pulmonary vascular disease caused by different 
etiological factors. The clinical manifestations of PAH 
include persistently elevated pulmonary artery pressure, 
which subsequently lead to right ventricular hypertrophy, 
right heart failure and even death (Chin, Rubin, 2008). 
Generally, one person with average pulmonary artery 
pressure in left ventricular catheter≥25 mm Hg at rest will 
be diagnosed with PAH (Hoeper et al., 2014; Barst et al., 
2004). PAH is a highly malignant disease with poor 
prognosis and high mortality (Fenstad et al., 2013). 
The traditional drugs for PAH include anticoagulants, 
cardiotonics, diuretics etc. whose therapeutic mechanism 
is mainly reducing pulmonary artery pressure. Although 
these treatments can relieve and improve clinical 
symptoms of PAH patients, they still cannot delay 
the worsening of PAH. With the deepening research 
on pathogenesis of PAH, new targeted drugs for 
PAH constantly emerge to extend the survival time. 
The classic novel targeted drugs for PAH include 
prostacyclin and its analogs, endothelin receptor 
antagonist, phosphodiesterase type-5 (PDE-5) inhibitors, 
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etc (Galiè et al., 2015; Gomberg, Olschewski, 2008; 
Rhodes et al., 2009; Archer, Michelakis, 2009).
Tadalafil (TDF), a long-term PED-5 inhibitor, is 
originally used to treat male erectile dysfunction, with 
therapeutic dose of 10 mg/d. It is approved for the treatment 
of PAH by the U.S. Food and Drug Administration in May 
2009. The corresponding therapeutic dose is 40 mg/d. TDF 
can significantly increase exercise tolerance in patients 
with PAH, improved flow-mediated vessel dilation and 
delay further deterioration of PAH without dietary effect 
(Oudiz et al., 2012; Galiè et al., 2009; Kloner, Mitchell, 
Emmick, 2003). Long-term TDF treatments are generally 
essential for PAH patients, during which obvious adverse 
reactions are observed including headache, indigestion, 
nasal congestion, etc (Carson et al., 2004). Further, the 
poor water solubility results in low bioavailability of 
TDF. So new dosage form of TDF is needed to improve 
the bioavailability and reduce side effects of long-term 
treatments, which have important clinical significance for 
the treatments of PAH.
At present, sustained release microspheres for 
inhalation made from biodegradable polymer material, 
combining advantages of local targeting administration 
with sustained release formulations have been paid great 
attention. First, drugs are delivered to the lesion directly 
by local targeted administration, which can reduce the 
dosage and systemic adverse reactions (Azarmi, Roa, 
Löbenberg, 2008). Second, sustained release preparation 
can prolong the duration of action. The drug concentration 
is maintained at a therapeutically effective concentration 
or more, reducing the frequency of administration, 
improving the therapeutic effect (Zeng, Martin, Marriott, 
1995; Hardy, Chadwick, 2000). Biodegradable materials 
commonly used include starch, chitosan, polylactic 
acid (PLA), poly (lactic-co-glycolic acid) (PLGA), 
etc (Freiberg, Zhu, 2004). Currently, PLGA with good 
biocompatibility and biodegradability has been one 
of the most commonly used biodegradable materials. 
PLGA is cleaved into a hydroxy acid and lactic acid in 
vivo. Subsequently, the resultants are transformed into 
carbon dioxide and water (Anderson, Shive, 2012). So no 
hazardous substance accumulates in the body. In addition, 
different release rate can be achieved by changing the ratio 
of lactic acid to glycolic acid (Park, 1995). Collectively, 
PLGA microspheres for pulmonary administration have 
the following advantages: (1) Both convenient usage 
and decreasing frequency of administration can increase 
patient compliance (Cook, Pannu, Kellaway, 2005); (2) 
The steady plasma concentration of drug within effective 
range can reduce side effects caused by rapid release of 
drug, which makes it possible to achieve a high security; 
(3) Drugs are directly delivered to the lesion to achieve a 
better therapeutic effect without hepatic first-pass effect; 
(4) The PLGA microspheres made from biodegradable 
material have a good biocompatibility; (5) The particle 
size is controllable, so the size of PLGA microspheres 
suitable for pulmonary administration can be achieved 
through optimization of technology and prescription; 
microspheres less than 1.4 μm are usually all through the 
pulmonary circulation, 7-14 μm microspheres mainly stay 
in the lungs, and the microspheres less than 3 μm remain 
in the liver and spleen mostly (Carvalho, Peters, Williams, 
2011). (6) The retention time of drugs in the lung can be 
greatly prolonged, so the drugs can be slowly released 
(Dunne, Corrigan, Ramtoola, 2000). 
The gold therapy for respiratory diseases is inhaled 
route of administration which is widely used for lung diseases 
(Sham et al., 2004; Ely et al., 2007; Kleinstreuer, Zhang, 
Donohue, 2008). Currently, the main pulmonary inhalation 
formulations include metered dose inhaler, atomization 
inhalant and dry powder inhalant. Compared with several 
other inhalants, powder inhalant is administrated by active 
inhalation. So there are no difficulties in synchronization 
between manual trigger and breathing (Watts, McConville, 
Williams, 2008). In this study, single-dose dry powder 
inhaler like Spinhaler and Rotahaler will be used for 
pulmonary administration. This paper aims to prepare 
tadalafil loaded PLGA microspheres for pulmonary 
inhalation. Subsequently, the physicochemical properties, 
micromeritic properties and release characteristic in vitro 
are studied and evaluated respectively. Tadalafil solution as 
the control group, pharmacokinetics and tissue distribution 
in Wistar rat are studied and evaluated after intratracheal 
instillation of tadalafil PLGA microspheres suspensions to 
explore the long-term sustained release characteristic and 
safety. This formulation can not only control the release of 
drugs but reduce systemic toxicity, which are be conducive 
to improving the therapeutic effect.
MATERIAL AND METHODS
Material
Tadalafil was provided by Qilu Pharmaceutical Co., 
Ltd. PLGA (50:50, Mw = 15000-25000) was purchased 
from Advanced Polymer Materials Inc. (Montreal, 
Canada). PVA (Alcoholysis degree: 87-89%) was obtained 
from the Sigma USA. Methylene chloride (99.9% HPLC 
grade) was purchased from Fu Yu Fine Chemical Co., Ltd, 
Tianjin, China. Acetone (analytical grade) was purchased 
from Laiyang Fine Chemical Plant, Laiyang, China. The 
other chemicals were of analytical reagent grade or higher.
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Methods
Preparation of TDF-PLGA-MS
Tadalafil loaded microspheres were prepared by 
modified emulsion-solvent evaporation method. The lipid 
phase and aqueous phase were prepared respectively. 5 mg 
of tadalafil and 30 mg of PLGA were weighted precisely 
and co-dissolved in 0.3 mL of acetone-methylene chloride 
(0.1:0.2) mixed solvent as lipid phase. In addition, 1.2 mL 
of 5 % (w/v) PVA solution was as aqueous phase. Then, the 
lipid phase was added into the aqueous phase dropwise and 
stirred (5000 rpm, 0.5 min) to form a primary emulsion by 
tissue tearor. The primary emulsion was poured into 18 mL 
of 2% PVA solution (dispersed phase) and stirred for 3 h 
at 25 ℃. The PLGA microspheres were obtained when 
organic solvents were removed by evaporation.
Optimization of formulation with orthogonal 
experimental design
Based on the investigation of single factor, four 
factors greatly affecting entrapment efficiency were 
chosen as research objects. They were (A) the ratio of drug 
to PLGA (w/w), (B) the concentration of PLGA (w/v), 
(C) the volume ratio of lipid to aqueous phase, (D) the 
volume ratio of aqueous to dispersed phase, respectively. 
Nine formulations were designed according to L9 (34) 
orthogonal design to screen the optimal formulation and 
process. With encapsulation efficiency as evaluation index, 
the factors and levels of the orthogonal design were listed 
in Table I.
Freeze-drying of TDF-PLGA-MS
In the freeze-drying process, mannitol (2%, w/v) 
was used as a cryoprotectant. First of all, 1mL of freshly 
prepared TDF-PLGA-MS suspension (contain 5 mg of 
tadalafil) were washed with distilled water three times 
and mixed with mannitol. Subsequently, the mixture were 
pre-frozen using an ultra-cold freezer (MDF-382E, Sanyo 
Electric Co., Ltd., Osaka, Japan) at -80 ℃ for 12 h. Then, 
the resultant samples were transferred to the lyophilizer 
(Alpha 1-2 LD, Christ, Germany) at -45 ℃ for 24 h. The 
lyophilized powder was collected for further experiments.
Characterization of TDF-PLGA-MS
Physical and chemical property
The morphology of TDF-PLGA-MS was examined 
using optical microscope (OM, Alphaphot-2 YS2, Nikon, 
Japan). Moreover, the powder samples of TDF-PLGA-MS 
were fixed on the spindle with double-sided adhesive. Then, 
the samples were plated under argon protection. Finally, the 
surface of the microspheres was observed under scanning 
electron microscopy (SEM, JSM-840A, Jeol, Tokyo, 
Japan) after the gold plating. The size distribution of the 
PLGA microspheres was determined using laser particle 
size analyzer (Mastersize 2000, Malvern, Britain). The 
pH value of TDF-PLGA-MS suspensions was determined 
using pH meter (FiveEasy, Mettler Toledo, Switzerland). 
The blank MS was prepared in the same process with 
drug-loaded TDF-PLGA-MS. Then, PLGA, TDF, physical 
mixture and TDF-PLGA-MS were characterized by DSC 
measurements (DSC822e, Mettler Toledo, Switzerland). 
These characterizations were used to examine the physical 
and chemical stability of the drug-loaded microspheres.
Determination of encapsulation efficiency (EE) and 
drug loading (DL)
The EE and DL of TDF-PLGA-MS were determined 
by ultraviolet spectrophotometry (TU-1810, Puxi, Beijing, 
China). Firstly, TDF-PLGA-MS suspension was centrifuged 
at 8000 rpm for 10 min. After discarding the supernatant, the 
precipitate was washed three times with distilled water. 13 
mg precipitate was precisely weighed, dissolved in dimethyl 
sulfoxide-acetonitrile (1: 1) in volumetric flask (10 mL) and 
diluted to volume. The absorbance was measured at 285 
nm. The EE and DL were calculated in accordance with the 
formula (1) and (2), respectively. 
   (1)
  (2)
where Wtheory, Wpractice and WPLGA are the weight of drug 
added, the weight of TDF in microspheres and the weight 
of PLGA added in system, respectively.




A (W/W) B (mg/mL) C (V/V) D (V/V)
1 1:6 60 1:2 1:5
2 1:8 80 1:4 1:10
3 1:10 100 1:6 1:15
Footer: A, B, C, D were (A) the ratio of drug to PLGA (w/w), 
(B) the concentration of PLGA (w/v), (C) the volume ratio of 
oil phase to aqueous phase, (D) the volume ratio of aqueous to 
dispersed phase, respectively.
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Micromeritic
Moisture content
The moisture content of dried powder has a great 
impact on atomization process: with the increase of 
moisture content, the powder is easy to assemble and 
hard to disperse. Therefore, it is hard to be atomized and 
emptied, resulting in a decrease of deposition on lesions 
(Lakio et al., 2015). So the moisture content of the powder 
has great influence on pulmonary administration. In this 
paper, we determined the moisture content using Karl-
Fisher Titrator (YT-11133F, Shanghai yutong instrument 
Factory). 0.5 g dried powder of microspheres was weighed 
precisely and placed in the titrator. Then, the moisture 
content was calculated after titration.
Bulk density
The bulk density is equal to the ratio of mass to 
volume of powder, indicating the bulkiness degree of 
powder (Lam et al., 2014). The smaller the bulk density 
is, the fluffier the powder is. So it is easier to disperse into 
fine particles and reach the lung. To some extent, this is 
good for reducing the residues in the respiratory tract. In 
this research, the bulk density of microspheres powder 
was measured by measuring cylinder method. 5.0 g of 
tadalafil microspheres powder was weighed precisely 
and placed into the measuring cylinder (10mL). At 5 cm 
away from the desktop, the measuring cylinder free fell 
vertically for three times. Then the volume of powder was 
recorded. The bulk density was calculated according to 
following equation.
ρ = W / V
where ρ, W and V are the bulk density, mass and volume 
of powder, respectively.
Repose angle
With  easy  ope ra t ion ,  l ow cos t  and  good 
reproducibility, the angle of repose of powder is 
commonly used to indicate flowability of powder 
(Wong, 2002). We measured the angle of repose of the 
microspheres powder using the funnel method. The 
funnel was fixed at a specified height above the right 
origin of a disc, a certain amount of microspheres powder 
fell freely from the funnel until a cone with certain 
radius (about 5 cm) was formed. Then the height of cone 
was determined and the angle of repose was calculated 
according to following equation.
tanθ = H / r
where θ, H and r are the angle of repose, height and radius 
of cone, respectively. Moreover, the angle of repose of less 
than 30 degrees indicates the powder flowability was good. 
When the angle of repose was less than 40 degrees, it is 
able to meet the production requirements for flowability. 
Aaerodynamic equivalent diameter
Due to different density and shape, powders with 
the same size of different materials have different settling 
velocity in the air, so the sedimentation site in respiratory 
tract is also different. In order to compare with each 
other, the concept of aerodynamic diameter is proposed. 
W. Stober defined the aerodynamic diameter of actual 
particle as the diameter of the spherical particle with a 
density of 1 g/cm3 and the same settling velocity as the 
actual particle. Compared with actual particle size, the 
aerodynamic diameter can properly describe the dynamic 
characteristics of pulmonary inhalation. The aerodynamic 
diameter is together determined by the geometric size 
and tapped density of particles (Salma et al., 2015). We 
calculated the aerodynamic diameter according to the 
following empirical formula of aerodynamic diameter (d’) 
estimated theoretical value (Wang, John, 1987).
where ρ  is the tapped density of TDF-PLGA-MS powders 
without mannitol, ρ1 = 1 g/cm3, d is the average geometric 
diameter of particles.
Atomization characteristics
Refering to relevant literatures and Chinese 
Pharmacopoeia (2010 edition), volume II, Appendix X, 
we made the atomization device to measure the uniform 
degree of smog after atomization. The experimental 
apparatus is shown in Figure 1. A certain amount of 
microspheres powder was weighed and filled into 
No. 3 capsule. Subsequently, the capsule was placed into 
the inhalation device after perforation. Then the inhalation 
device was connected with a 5000 mL glass bottle via 
valve. At the moment, the valve was closed. The glass 
bottle was vacuumized at the flow rate of 60 L/min. After 
switching on the valve, microspheres powder was ejected 
from inhalation device. The same operation was repeated 
for four times, and the duration was 1.5 s for each time. If 
powder formed uniform smog after ejection and no large 
particles were found after deposition, which indicated a 
very easy atomization. This moment, the atomization level 
was “3”. If most of the powder formed uniform smog, 
only a small amount of large particles were found on the 
bottom, which indicated an easy atomization. At the same 
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time, the atomization level was “2”. If most of the powder 
formed large particles and deposited on the bottom, which 
indicated a atomization. At the moment, the atomization 
level was “1”.
Emptying rate
The same operation was repeated according to 
“2.2.5.5”. A certain amount of microspheres powder was 
weighed precisely and filled into empty capsule. At the 
same time, the mass of empty capsule before and after use 
was precisely weighed as well. Emptying rate (ER) was 
calculated according to the following formula. 
ER = [(w1-w2) / (w1-w3)] × 100%
where w1, w2 and w3 were the mass of microspheres 
powder filled into capsule, empty capsule before and after 
use, respectively. 
The drug release experiment in vitro
The release experiment in vitro was performed 
using dynamic dialysis method. The right amount of 
microspheres powder (about containing tadalafil 448 μg, 
equivalent to the same amount of tadalafil solution) was 
precisely weighed and suspended in 1mL phosphate buffer 
(pH7.4, containing 2% Tween-80 and 0.3% NaN3). The 
resultant suspension was placed in dialysis bags with 
8~14 kDa molecular weight cut-off. The dialysis bags 
were incubated in 10 mL of phosphate buffer (pH 7.4, 
containing 2% Tween-80 and 0.3% NaN3) which was 
filled in well-closed tubes as dissolution medium. The 
tubes were placed in a constant temperature water bath 
oscillator with 100 rpm at 37 ± 1 ℃. An appropriate 
amount of tadalafil was weighed and dissolved in dimethyl 
sulfoxide-acetonitrile (1:1). Then, the resultant solution 
was diluted with dissolution medium. Finally, the tadalafil 
solution with a concentration of 448 μg/mL was obtained. 
With 1 mL tadalafil solution (448 μg/mL) as control group, 
4 mL dispersion sample was withdrawn at scheduled time 
intervals (0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 
198 and 240 h) and its drug content was determined at 
285 nm by UV method as described above. Equal volume 
of fresh dissolution medium was added into the tubes to 
maintain the constant volume. This drug-release assay was 
performed in triplicate. The cumulative release percentage 
was calculated to draw in vitro release profile.
Furthermore, we applied Zero-order model, 
First-order model, Higuchi model, Weibull model, 
Ritger-Peppas model to fit the release data, respectively. 
Moreover, r was used to choose the optimal release model. 
The larger the r value was, the closer the model was to the 
true model.
Animals
Wistar rats (weighted between 160 ~ 200 g, 
provided by the Medical Animal Test Center of Shandong 
University) were used for the study of Pharmacokinetics 
and tissue distribution. The animals were fasted for 12 h 
before drug administration. The animal experiment 
protocol was reviewed and approved by the Institutional 
Animal Care and Use Committee of Shandong University.
Pharmacokinetics and tissue distribution studies 
in rats
Six healthy wistar rats were randomLy divided 
into two groups. Control group was treated with tadalafil 
solution by intratracheal instillation while study group was 
treated with TDF-PLGA-MS suspension. The tadalafil 
doses were all 10 mg/kg. Blood samples were taken from 
the neck sinus at scheduled time points (0.5, 1, 2, 4, 6, 8, 
12, 24, 36 and 48 h) and placed into micro-tubes containing 
sodium heparin as anticoagulant. 0.3 mL of acetonitrile 
was added to an aliquot (0.2 mL) of each plasma sample 
and mixed for 4 min by vortex to extract tadalafil. The 
supernatants were withdrawn after centrifugation (12000 
rpm, 10 min). Finally, the samples were filtrated with 
0.22 μm membrane filter and analyzed by HPLC using 
Shimadzu LC-20AT pump and Shimadzu SPD -M20A 
detector set at 285 nm. A Platisil TM-ODS column 
(4.6 mm × 250 mm, 5 μm) was used. The mobile phase 
involved acetonitrile - 0.1% acetic acid aqueous solution 
mixture at 42:58 (V/V). The flow rate was 1.0 mL/min 
at 35 ℃. Aliquots of supernatants (20 μL) were loaded 
FIGURE 1 - Experimental devices of emptying rate and 
atomization determination A:Valve; B:Inhaler; C:Vacuum 
indicator; D:Vacuum pump.
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on the HPLC. The linear regression equations in the 
plasma and lung were A = 44.595C-745.3, r = 0.9998 
and A = 37.946C + 1081.3, r = 0.9998, respectively. The 
results of methodology showed that this method fulfill the 
requirement of biological samples determination.
Another 54 healthy wistar rats were also randomLy 
divided into two groups. Control group and study group 
were treated with tadalafil solution and TDF-PLGA-MS 
suspension by intratracheal instillation, respectively. 
After stitching wounds, rats were killed at scheduled time 
(0.5, 2, 4, 8, 24, 48, 96, 144 and 240 h). The lungs, heart, 
liver, spleen and kidney of each rat were rapidly excised 
following blood collection, and immediately washed twice 
with normal saline (0.9% NaCl). Subsequently, tissue 
samples were wiped with filter paper, precisely weighed 
and homogenized with 1.0 mL normal saline (0.9% NaCl), 
except for liver (2 mL). 0.3 mL of acetonitrile was added 
to an aliquot (0.2 mL) of each sample and mixed for 
4 min by vortex to extract tadalafil. The supernatants were 
withdrawn after centrifugation (12000 rpm, 10 min) and 
analyzed by HPLC method described above.
Statistical analysis
Data were plotted as mean ± standard deviation 
(S.D). The statistical analysis of significance was 
performed using unpaired Student’s t-test. A P < 0 05 
indicated significant difference. An analysis of variance 
(ANOVA) test was also used if necessary. Pharmacokinetic 
parameters were obtained using DAS2.0 (drug and 
statistics for windows) program. A Re>1 indicated tissue 
targeting.
RESULTS AND DISCUSSION
Results of the test of orthogonal design of 
VANH-Lip
The EE and DL of nine formulations were determined 
using UV method described above and calculated by 
range analysis. The results were listed in Table II. Results 
indicated that the effect of (B) the concentration of PLGA 
was extremely significant, followed by (D) the volume 
ratio of aqueous to dispersed phase, (A) the ratio of drug 
to PLGA (w/w), (C) the volume ratio of lipid to aqueous 
phase, respectively. k1, k2, k3 are the weighted average 
value of three factors. The levels effects of each factor 
were as follows: (A) 1 > 3 > 2, (B) 3 > 2 > 1, (C) 1 > 2 > 3, 
(D) 1> 2> 3. Therefore, the optimal prescription was 
A1B3C1D1. Based on the actual situation, the ratio of 
drug to lipid was properly adjusted from 1:10 to 1:8 
to save the material and improve DL. From the above, 
the optimal formulation and process were as follows: 
(A) 1: 8, (B) 100 mg/mL, (C) 1: 4, (D) 1: 5. 
The EE and DL of the TDF-PLGA-MS according to 
the optimal formulation and process were (81.68 ± 0.55) % 
and (8.52 ± 0.06) %, respectively. The optimal formulation 
had a good feasibility and repeatability. Moreover, the EE 
and DL of microspheres were relatively high, which would 
be helpful to improve pharmaceutical and pharmacological 
effects in curing PAH.
Characterization of TDF-PLGA-MS
Physical and chemical property
The appearance photographs of TDF-PLGA-MS 
freeze-dried powder were shown in Figure 2. The white 
freeze-dried powder appeared as full, fluffy and non-
caking. The morphology of TDF-PLGA-MS was observed 
using SEM and microscope. As shown in Figure 3, the 
TDF-PLGA-MS were spherical particles and have no 
significant difference in morphology before and after 
lyophilization. Microspheres were still spherical after 
redissolving. The SEM image showed that most of the 
microspheres were smooth sphere with approximate size 
and uniform dispersion. No adhesion was found among 
the microspheres.
TABLE II - Results of the test of orthogonal design of TDF-
PLGA-MS
No. A B C D EE(%)
1 1 1 1 1 71.11
2 1 2 2 2 69.82
3 1 3 3 3 76.51
4 2 1 2 3 55.89
5 2 2 3 1 69.42
6 2 3 1 2 75.36
7 3 1 3 2 56.40
8 3 2 1 3 67.64
9 3 3 2 1 81.93
k1 72.480 61.133 71.370 74.153
k2 66.890 68.960 69.213 67.193
k3 68.657 77.933 67.443 66.680
R 5.590 16.800 3.927 7.743
Footer: A, B, C, D are (A) the ratio of drug to PLGA (w/w), 
(B) the concentration of PLGA (w/v), (C) the volume ratio of 
oil phase to aqueous phase, (D) the volume ratio of aqueous 
to dispersed phase, respectively. k1, k2, k3 are the weighted 
average value of four factors with three levels.
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The size of TDF-PLGA-MS was unformLy 
distributed as shown in Figure 4. The particle sizes of fresh-
prepared and lyophilized microspheres from Malvern Laser 
Particle Size Analyzer 2000 were (10.04 ± 0.09) μm and 
(10.29 ± 0.25) μm, which was consistent with the results of 
SEM. No significant difference in particle size was found 
between fresh-prepared and lyophilized microspheres. The 
D90 value was about 20 μm, which indicated a relatively 
narrow distribution. The pH value of TDF-PLGA-MS was 
6.95 ± 0.05, meeting the physiological pH in the body. 
Collectively, the TDF-PLGA-MS prepared in this study 
was suitable for pulmonary administration.
DSC
The DSC analysis were performed on tadalafil 
raw material, blank microspheres, the physical mixture 
of tadalafil and blank microspheres, and freeze-dried 
TDF-PLGA-MS to inspect the melting, crystallization 
behavior and polymorphism. The DSC thermograms were 
shown in the Figure 5. The endothermic peak at 50 °C is 
the melting point of PLGA. The DSC results indicated 
that tadalafil had a distinct endothermic peak at 305 °C 
and an exothermic peak at 376 °C. In addition, there 
were similar peaks to tadalafil except endothermic peak 
of PLGA at 315  °C in the physical mixture, which may 
reveal that tadalafil was in crystalline state in the physical 
mixture. However, no peaks of tadalafil were observed in 
the DSC curve of tadalafil microspheres, which indicated 
that tadalafil was not in crystalline state but dispersed in 
microspheres. 
Micromeritic characteristics
The micromeritic characteristics contribute to the 
FIGURE 2 - The appearance of TDF-PLGA-MS.
FIGURE 3 - Microscopy photograph of TDF loaded PLGA microspheres: (A) fresh-prepared; (B) suspension of freeze-dried 
powder; (C) the SEM of freeze-dried powder.
FIGURE 4 - Size distribution of TDF loaded PLGA microspheres: (A) Microspheres after freeze-drying; (B) Microspheres before 
freeze-drying.
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quality and therapeutic effect of inhalation, involving 
moisture content, angle of repose, bulk density, particle size 
aerodynamics, emptying rate, atomization characteristics, 
etc. The results in Table III showed that TDF-PLGA-MS 
had a low moisture content, which was conducive to the 
stability, atomization, and emptying of microspheres 
powder. The average bulk density was less than 190 mg/mL, 
which indicated that the microspheres powder was fluffy 
and easily dispersed. The average angle of repose was 
less than 38 degrees, indicating that the microspheres 
powder had a relatively good flowability. The flowability 
of microspheres powder still need to be improved with 
additament. The particles with aerodynamic diameter 
ranging from 1 to 5 μm can readily accumulate in the 
deep region of lung (Kandasamy, Chandrasekaran, 2013; 
Varshosaz et al., 2017). The aerodynamic diameter of 
tadalafil microspheres prepared in this study was 3.92 μm, 
so the microspheres powder was easy to accumulate in 
lung. The atomization characteristics determine whether 
the powder quickly disperses into alveoli by atomization 
apparatus. The tadalafil microspheres powder had a very 
easy atomization in experiment, so the atomization level 
accorded with “3”. The emptying rate was 95.41%, which 
revealed that the TDF-PLGA-MS could be fully emptied. 
From the above, the TDF-PLGA-MS prepared in this study 
can meet the requirements of inhalation for pulmonary 
administration.
Drug release in vitro
The in vitro release profile of TDF-PLGA-MS 
was shown in Figure 6. Results indicated that more than 
80% of the drug released from tadalafil solution within 
4 h. The cumulative release reached 98.72% within 8 h. 
The release of tadalafil (<100%) from solution was in 
accordance with the Weibull and Ritger-Peppas model at 
the same time and could be expressed using the following 
equations, respectively: ln(1/(1-Q/100) = 0.81lnt – 0.3981 
and lnQ = 0.3835lnt + 3.8577, (r = 0.9911). The equations 
showed that the release of tadalafil from solution 
accorded with Fick’s diffusion mechanism. Compared 
with tadalafil solution, only 19.32% of the drug released 
from TDF-PLGA-MS in 4 h. The cumulative release 
reached 30.48% in 8 h. The cumulative release of tadalafil 
from microspheres was 84.06% within 10d, indicating a 
prolonged release of tadalafil from TDF-PLGA-MS as 
compared to the tadalafil solution. The release of tadalafil 
from microspheres (<85%) was consistent with the 
Weibull model and could be expressed using the following 
equation: ln(1/(1-Q/100) = 0.5538lnt – 2.3209, r = 0.9968. 
The equations showed that the release of tadalafil from 
microspheres accorded with Fick’s diffusion mechanism, 
too. In addition, somewhat burst release was found in the 
release behavior of TDF-PLGA-MS, which was in favour 
of quickly reaching effective blood concentrations and 
improving therapeutic effect (Acharya, Park, 2006). 
Pharmacokinetics and tissue distribution
Pharmacokinetics
The blood concentration-time curves of tadalafil 
in rats after intratracheal instillation were shown in 
Figure 7. Data suggested that the blood concentration 
increased rapidly after intratracheal instillation of tadalafil 
solution. The concentration of tadalafil in blood reached 
724.17 ng/mL in 0.5 h. The main reason was that there 
were abundant blood capillaries in lung with large surface 
area which were good for the rapid absorption of drug 
(Ryan et al., 2013). However, the concentration of tadalafil 
from TDF-PLGA-MS was only 65.82 ng/mL within 0.5 h 
after instillation. Then the blood concentration slowly 
went up with the release of drug in the microspheres. A 
decrease could be seen when the rate of release was lower 
FIGURE 5 - The results of DSC of PLGA microspheres:(A) 
blank microspheres; (B) tadalafil; (C) mixture; (D) tadalafil 
loaded microspheres).
TABLE III - Micromeritic of TDF-PLGA-MS (n=3)
Sample Average±SD
Moisture content (%) 
Bulk density (mg/mL) 
Repose angle (°) 
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than that of elimination in 12 h. In comparison with the 
tadalafil solution, the tadalafil microspheres had little 
leakage in blood circulation, which was helpful to improve 
the utilization of drugs and reduce the systematic adverse 
reactions.
Tissue distribution
The tissue distributions of tadalafil from solution 
and microspheres after intratracheal instillation were 
shown in Figure 8. Remarkably, the drug distribution in 
different tissues was also different between the tadalafil 
solution and the tadalafil microspheres. Briefly, the 
concentration of drug from microspheres in each tissue 
clearly decreased compared with solution group, which 
proved that microspheres pulmonary administration could 
reduce the drug distribution in other tissues except lung. 
The drug concentration versus time curve in lung was 
shown in Figure 9. The tadalafil concentration in lung 
dramatically decreased after intratracheal instillation of 
tadalafil solution. The drug concentration in 0.5 h and 
48 h were 52732.34 ng/g and 481.86 ng/g, respectively. 
However, after instillation of TDF-PLGA-MS, the drug 
concentrations in 0.5 h and 48 h were 183458.83 ng/g and 
10428.55 ng/g, which were 3.5 and 21.6 times those of the 
solution group, respectively. The concentriation of tadalafil 
from microspheres in lung still reached 866.69 ng/g after 
10 d which was higher than that from tadalafil solution 
FIGURE 6 - In vitro release profile of TDF from TDF-PLGA-
MS and TDF-Sol.
FIGURE 7 - Mean drug concentration–time curves of TDF in 
plasma after intratracheal instillation of TDF -Sol and TDF-
PLGA-MS.
FIGURE 8 - Tissue distribution at different time points in rat after 
intratracheal instillation: (A) TDF-Sol; (B) TDF - PLGA-MS.
FIGURE 9 - Mean residual concentration–time curves of TDF 
in lung after intratracheal instillation of TDF -Sol and TDF-
PLGA-MS.
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in 48 h. It indicates that the TDF-PLGA-MS prepared 
in this study can slowly release the drug for 10 d in the 
lung. So tadalafil microspheres are with good sustained 
-release effect.
The pharmacokinetic parameters were calculated 
by DAS 2.0 software and shown in Table IV. The 
pharmacokinetic in the plasma and lung were all 
in accordance with two-compartment model. After 
intratracheal instillation of TDF-PLGA-MS, the t1/2α 
and t1/2β were 10.128 h and 69.135 h, which were 7.22 
and 3.10 times those of the solution group, respectively. 
The MRT0-∞ of 28.244 h was 3.96 times that of solution 
group. The Cmax and AUC0-∞ in lung were 183.459 μg/g 
and 4060.097 mg/L*h, which were 3.48 and 16.36 times 
those of solution group, respectively. From the above, the 
TDF-PLGA-MS for pulmonary administration can clearly 
prolong the residence time of tadalafil in lung to maintain 
a relatively high concentration for a long time, which 
contributes to reducing the leakage in blood circulation 
and administration dosage. Thereby, the treatment effect 
for PAH will be improved and systemic side effects will 
also be reduced at the same time.
In this study, the Re was used to evaluate the 
targeting characteristics of TDF-PLGA-MS. The Re of 
TDF-PLGA-MS after intratracheal instillation was listed 
in Table V. The Re >1 indicated the tissue targeting. The Re 
in heart, spleen, liver and kidneys were 0.354, 0.451, 0.451 
and 0.699, respectively. Therefore, no or low targeting 
characteristics were found in these tissues. The Re in 
these tissues were all less than 1, which was helpful to 
reduce the potential toxicity especially in liver and kidney. 
However, the Re in lungs was 16.358, which indicated 
the great tissue targeting characteristics. To sum up, the 
TDF-PLGA-MS can reduce the drug distribution in non-
target organ and greatly increase the drug concentration in 
lungs to improve the therapeutic effect of tadalafil for PAH.
CONCLUSIONS AND OUTLOOK
In this study, the TDF-PLGA-MS were prepared 
using modified emulsion-solvent evaporation method 
to be applied to pulmonary delivery. The particle size of 
microspheres could be easily controlled (Emami et al., 
2009). The tadalafil microspheres prepared in this study 
can meet the requirements of pulmonary inhalation. 
The sustained release effect of tadalafil microspheres in 
lungs can last 10 days after pulmonary administration. 
The pharmacokinetics results show little leakage of 
tadalafil from microspheres is found in blood circulation. 
Moreover, tadalafil from microspheres can be retained 
in lungs for a long time and slowly release to reduce the 
adverse reactions and improve the therapeutic effect for 
PAH. Experimental results of tissues distribution show 
that the drug concentration in heart, liver, spleen and 
kidney are reduced but increased in lungs. So the tadalafil 
microspheres can reduce the drug distribution in non-target 
organs and greatly increase the drug retention in lungs to 
improve the therapeutic effect of tadalafil for PAH. At the 
same time, the potential toxicity especially in liver and 
kidney will be reduced. 
Although the dose for treating PAH is greater 
than that for male erectile dysfunction, with a long-
acting release function of microspheres, the drug from 
TABLE IV - The pharmacokinetic parameters in lung of TDF 





CL (L/h/kg) 0.002±0.001 0.040±0.007
AUC 0-∞(mg/L*h) 4060.097±1.995 248.199±0.897
MRT 0-∞(h) 28.244±0.528 7.140±0.108
Tmax(h) 11.000±0.193 0.500±0.098
Cmax (μg/g) 183.459±0.894 52.732±0.627





Heart 12101.169±2.512 33005.105±2.578 0.367
Liver 16201.364±1.238 36635.684±2.689 0.442
Spleen 9285.362±0. 859 20591.025±1. 859 0.451
Kidney 10501.217±3.198 15025.624±0.892 0.699
Lung 4060096.878±5.589 248198.762±3.127 16.358
Footer: Re, namely relative uptake rate.
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microspheres slowly release into the lung. Only an 
aliquot of tadalafil does leak into the systemic circulation. 
Therefore, it is less likely to lead to male erection. In 
summary, the TDF-PLGA-MS inhalant is a sustained 
release formulation which can be used for pulmonary 
delivery and of great significance for future clinical 
application. 
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